2 recruiting. 1 Phase 2, 1 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 1 | Recruiting 1 |
| Phase 3 | 1 | Recruiting 1 |
Follow Ji Dongmei: new trials by email
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Cetuximab Combined With Pembrolizumab or Finotonlimab and Chemotherapy in R/M HNSCC cetuximab+PD-1 mAb(Pembrolizumab/Finotonlimab)+chemotherapy, PD-1 mAb (Pembrolizumab/Finotonlimab) + chemothearpy - Squamous Cell Carcinoma of Head and Neck | Phase 3 | Recruiting | Ji Dongmei | 316 | 2026-09-15 | 2026-10-02 |
| The Safety and Efficacy of MRG003 With or Without Putrelimab in Recurrent or Metastatic Salivary Gland Cancer: a Single-center, Open-label Cohort Study MRG 003, Pucotenlimab - Salivary Gland Carcinomas | Phase 2 | Recruiting | Ji Dongmei | 90 | 2026-03-19 | 2026-04-01 |
Squamous Cell Carcinoma of Head and Neck (1)
pembrolizumab (1)
China (2)